Ikena Oncology Reports Second Quarter 2024 Financial Results
Ikena Oncology Reports Second Quarter 2024 Financial Results
Strong financial position with $145 million in cash and investments at close of second quarter
第二季度結束時，現金和投資總額爲14500萬美元，財務狀況穩健。
BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities.
2024年8月8日，美國波士頓（GLOBE NEWSWIRE）——Ikena Oncology, Inc.（納斯達克：IKNA，「Ikena,」「公司」）今天宣佈了截至2024年6月30日的第二季度財務業績，併發布了關於其正在進行的活動的最新進展。
Pipeline Updates
管線更新
- Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety evaluation period
- Promising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the blood
- In May 2024, the Company announced the discontinuation of the IK-930 clinical program
- Ik-595在RAS和RAF突變癌症患者中的一期研究中，劑量遞增繼續進行，多個隊列已經通過了安全評估期。
- 觀察到具有前瞻性的早期藥代動力學（PK）和藥效學（PD）活性，血液中的目標調節與劑量相關。
- 公司宣佈停止Ik-930臨床計劃。
Corporate Updates
公司更新
- In May 2024, the Company announced it was evaluating a range of potential strategic options to maximize shareholder value, and implemented a 53% workforce reduction
- In July 2024, the Company announced the appointment of Jotin Marango to serve as Chief Operating Officer, in addition to his roles as the Company's Chief Financial Officer and Head of Corporate Development
- 公司宣佈評估一系列潛在的戰略選擇，以實現股東價值最大化，並實施了53%的員工裁員。
- 2024年7月，公司宣佈任命Jotin Marango擔任首席運營官，同時擔任公司首席財務官和企業發展主管。
Financial Results for the Quarter Ended June 30, 2024
2024年6月30日結束的財務結果
As of June 30, 2024, the Company had cash, cash equivalents, and marketable securities of $145.4 million.
截至2024年6月30日，公司的現金、現金等價物和市場證券總額爲14540萬美元。
Research and development expenses for the three months ended June 30, 2024 and 2023 were $9.8 million and $15.2 million, respectively.
2024年6月30日和2023年6月30日的研發費用分別爲980萬美元和1520萬美元。
General and administrative expenses for the three months ended June 30, 2024 and 2023 were $5.3 million and $5.3 million, respectively.
2024年6月30日和2023年6月30日的總務及管理費用分別爲530萬美元。
Restructuring and other costs for the three months ended June 30, 2024 were $0.7 million.
2024年6月30日的重組和其他成本爲70萬美元。
The Company reported a net loss for the three months ended June 30, 2024 and 2023 of $13.7 million and $17.1 million, respectively.
公司報告2024年6月30日和2023年6月30日的淨虧損分別爲1370萬美元和1710萬美元。
About Ikena Oncology
Ikena Oncology develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Ikena aims to utilize its depth of institutional knowledge and breadth of tools to efficiently develop the right drug using the right modality for the right patient. To learn more, visit .
Ikena Oncology致力於開發針對癌症生長、擴散和治療抵抗節點的不同化療法，旨在利用其豐富的機構知識和廣泛的工具，以高效地開發適合特定患者的合適藥物。欲了解更多信息，請訪問。
本新聞稿包含根據1995年修訂版私人證券訴訟改革法第27A條和第21E條的前瞻性聲明，包括但不限於暗示和明示的關於：公司正在追求的靶向腫瘤項目的時間和進展；公司對其靶向腫瘤項目的治療效益的預期；以及公司能夠識別任何潛在戰略選擇並最大化股東價值的能力。這些詞語「可能」、「將」、「可以」、「會」、「應該」、「期望」、「計劃」、「預期」、「打算」、「相信」、「估計」、「預測」、「計劃」、「潛力」、「持續」、「靶向」及類似表達意圖的詞語，是爲了識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些識別詞語。本新聞稿中的任何前瞻性聲明都是基於管理層目前的期望和信念，並受一系列風險、不確定性和重要因素的影響，這些風險、不確定性和重要因素可能導致實際事件或結果與本新聞稿中任何前瞻性聲明所表達或暗示的事件或結果有所不同，其中包括但不限於公司目前的研究和開發項目和臨床試驗的時間、進展、結果和成本；公司識別、實施和實現任何戰略交易的預期收益；公司獲得爲其完成後續開發和商品化其產品候選藥物所必需的運營資金；公司獲得並維持其產品候選藥物的監管批准；公司實施公司的商業模式和業務、產品候選藥物的戰略計劃；以及其他與Ikena季度報告中「風險因素」部分中討論的因素有關的因素，該季度報告已在美國證券交易委員會（SEC）備案，並受任何隨後的SEC備案的更新所修改。您不應該過分依賴任何前瞻性聲明，這些聲明僅在其作出時有效。公司明確放棄公開更新或修訂任何這些聲明，以反映任何期望或事件、條件或情況的變化，這些聲明可能是基於或可能影響實際結果的可能性與在前瞻性陳述中設定的結果不同。本新聞稿中包含的任何前瞻性聲明僅代表公司本日的觀點，不應被視爲代表其日後觀點，公司明確不承擔更新任何前瞻性聲明的義務。
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding: the timing and advancement of the targeted oncology program that the Company is pursuing; the Company's expectations regarding the therapeutic benefit of its targeted oncology programs; and the Company's ability to identify any potential strategic options and maximize shareholder value. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing, progress, results, and cost of the Company's current research and development programs and clinical trials; the Company's ability to identify, implement and realize the anticipated benefits from any strategic transaction; the Company's ability to obtain funding for its operations necessary to complete further development and commercialization of its product candidates; the Company's ability to obtain and maintain regulatory approval of its product candidates; the implementation of the Company's business model, and strategic plans for its business and product candidates; and other factors discussed in the "Risk Factors" section of Ikena's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, which is on file with the Securities and Exchange Commission (SEC), as updated by any subsequent SEC filings. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.
前瞻性聲明
Rebecca Cohen
Investor and Media Contact:
Rebecca Cohen
rcohen@ikenaoncology.com
投資者和媒體聯繫人：
rcohen@ikenaoncology.com
rcohen@ikenaoncology.com
| Selected Financial Information | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Selected Statement of Operations Items: | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Collaboration revenue | $ | — | $ | 2,004 | $ | — | $ | 7,316 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 9,832 | 15,172 | 19,477 | 30,723 | ||||||||||||
| General and administrative | 5,308 | 5,322 | 11,307 | 10,598 | ||||||||||||
| Restructuring and other charges | 683 | — | 3,265 | — | ||||||||||||
| Total operating expenses | 15,823 | 20,494 | 34,049 | 41,321 | ||||||||||||
| Loss from operations | (15,823) | (18,490) | (34,049) | (34,005) | ||||||||||||
| Other income (expense) | 2,155 | 1,375 | 4,262 | 2,671 | ||||||||||||
| Loss before income taxes | (13,668) | (17,115) | (29,787) | (31,334) | ||||||||||||
| Income tax expense | (62) | — | (89) | — | ||||||||||||
| Net loss | $ | (13,730) | $ | (17,115) | $ | (29,876) | $ | (31,334) | ||||||||
| Net loss per share: | ||||||||||||||||
| Net loss per share- basic and diluted | $ | (0.28) | $ | (0.44) | $ | (0.62) | $ | (0.83) | ||||||||
| Weighted-average common shares outstanding, basic and diluted | 48,258,111 | 39,292,710 | 48,258,111 | 37,783,486 | ||||||||||||
| 財務精選信息 | ||||||||||||||||
| （以千爲單位，除股份數和每股數據外） | ||||||||||||||||
| (未經審計) | ||||||||||||||||
| 精選的經營業績項目： | 截至2024年6月30日的三個月 | 截至2024年6月30日的六個月 | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| 合作收入 | $ | — | $ | 2,004 | $ | — | $ | €7,316 | ||||||||
| 營業費用： | ||||||||||||||||
| 研發 | 9,832 | 15,172 | 19,477 | 30,723 | ||||||||||||
| 普通和管理 | 5,308 | 5,322 | 11,307 | 10,598 | ||||||||||||
| 重組和其他費用 | 683 | — | 3,265 | — | ||||||||||||
| 營業費用總計 | 15,823 | 20,494 | 34,049 | 41,321 | ||||||||||||
| 經營虧損 | (15,823) | （18,490） | (34,049) | (34,005) | ||||||||||||
| 其他費用收益 | 2,155 | 1,375 | 4,262 | 2,671 | ||||||||||||
| 稅前虧損 | (13,668) | (17,115) | (29,787) | (31,334) | ||||||||||||
| 所得稅費用 | (62) | — | (89) | — | ||||||||||||
| 淨虧損 | $ | (13,730) | $ | (17,115) | $ | （29,876） | $ | (31,334) | ||||||||
| 每股淨虧損: | ||||||||||||||||
| 每股基本和稀釋淨虧損 | $ | （-0.28） | $ | (0.44) | $ | (0.62) | $ | (0.83) | ||||||||
| 基本和稀釋加權普通股份 | 48,258,111 | 39,292,710 | 48,258,111 | 37,783,486 | ||||||||||||
| Selected Balance Sheet Items: | June 30, 2024 |
December 31, 2023 |
||||||
| Cash, cash equivalents, and marketable securities | $ | 145,419 | $ | 175,465 | ||||
| Total assets | $ | 157,485 | $ | 192,092 | ||||
| Total liabilities | $ | 14,626 | $ | 22,335 | ||||
| Total stockholders' equity | $ | 142,859 | $ | 169,757 | ||||
| 選定資產負債表項目： | 6月30日, 2024 |
12月31日 2023 |
||||||
| 現金、現金等價物和可交易證券 | $ | 145,419 | $ | 175,465 | ||||
| 總資產 | $ | 157,485 | $ | 192,092 | ||||
| 負債合計 | $ | 14,626 | $ | 22,335 | ||||
| 股東權益合計 | $ | 142,859 | $ | 169,757 | ||||
譯文內容由第三人軟體翻譯。
